Bioxytran (BIXT) Share-based Compensation (2010 - 2026)
Bioxytran (BIXT) posted Share-based Compensation of $35838.0 for Q1 2026, down 43.69% sequentially from $63645.0 in Q4 2025, and down 60.75% YoY from $91300.0 in Q1 2025.
Bioxytran (BIXT) Share-based Compensation (2010 - 2026) Analysis & Trends
Bioxytran has reported Share-based Compensation for 14 years, with the latest figure at $35838.0 in Q1 2026.
- Quarterly Share-based Compensation fell 60.75% year-over-year to $35838.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114937.0 (down 7.9% YoY) and the FY2025 annual result came in at $170399.0, down 14.66% from the prior year.
- Share-based Compensation retreated to $35838.0 in Q1 2026 per BIXT's latest filing, from $63645.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.0 million in Q4 2023 and troughed at -$50033.0 in Q2 2025.
- A 5-year average of $249656.9 and a median of $35838.0 in 2026 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation surged 114058.19% in 2023, then tumbled 567.99% in 2025.
- Over 5 years, Share-based Compensation stood at -$2648.0 in 2022, then soared by 114058.19% to $3.0 million in 2023, then plunged by 99.52% to $14394.0 in 2024, then jumped by 342.16% to $63645.0 in 2025, then slumped by 43.69% to $35838.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $35838.0, $63645.0, and $65487.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 30,515.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35,838.00 |
| Mar 31, 2026 | 35,838.00 |
| Dec 31, 2025 | 63,645.00 |
| Dec 31, 2025 | 63,645.00 |
| Sep 30, 2025 | 65,487.00 |
| Sep 30, 2025 | 65,487.00 |
| Jun 30, 2025 | -50,033.00 |
| Jun 30, 2025 | -50,033.00 |
| Mar 31, 2025 | 91,300.00 |
| Mar 31, 2025 | 91,300.00 |
| Dec 31, 2024 | 14,394.00 |
| Dec 31, 2024 | 14,394.00 |
| Sep 30, 2024 | 8,416.00 |
| Sep 30, 2024 | 8,416.00 |
| Jun 30, 2024 | 10,691.00 |
| Jun 30, 2024 | 10,691.00 |
| Mar 31, 2024 | 764,306.00 |
| Mar 31, 2024 | 764,306.00 |
| Dec 31, 2023 | 3.02 Mn |
| Dec 31, 2023 | 3.02 Mn |